Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

Copanlisib, an intravenously administered agent with inhibitory activity that predominantly targets the alpha and delta isoforms of phosphoinositol 3-kinase, was granted accelerated approval by the United States Food and Drug Administration on the basis of its activity in the third-line treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheson, Bruce D., O’Brien, Susan, Ewer, Michael S., Goncalves, Marcus D., Farooki, Azeez, Lenz, Georg, Yu, Anthony, Fisher, Richard I., Zinzani, Pierre L., Dreyling, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642803/
https://www.ncbi.nlm.nih.gov/pubmed/30584024
http://dx.doi.org/10.1016/j.clml.2018.11.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642803/
https://www.ncbi.nlm.nih.gov/pubmed/30584024
http://dx.doi.org/10.1016/j.clml.2018.11.021

Ejemplares similares